Comparative Pharmacology
Head-to-head clinical analysis: CYCLOSET versus KYNMOBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOSET versus KYNMOBI.
CYCLOSET vs KYNMOBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
Apomorphine is a non-ergoline dopamine receptor agonist with high affinity for D4 and moderate affinity for D2, D3, D5, and D1 receptors. It also has affinity for serotonergic (5-HT1A, 5-HT2A, 5-HT2B) and adrenergic (α1, α2) receptors. It improves motor function in Parkinson disease by stimulating striatal dopamine receptors.
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
Sublingual film: 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg as a single dose for acute off episodes; may repeat once within 4 hours if inadequate response; maximum 30 mg per dose and 3 doses per day.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
The terminal elimination half-life of apomorphine is approximately 40 minutes. This short half-life necessitates continuous administration via subcutaneous infusion for sustained clinical effect.
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
Apomorphine is predominantly metabolized in the liver. Renal excretion accounts for approximately 80% of the dose, with 10% excreted as unchanged drug and 70% as metabolites. Biliary/fecal excretion accounts for the remaining 20%.
Category C
Category C
Dopamine Agonist / Antidiabetic
Dopamine Agonist